C26H27FN10
Neat
498.57
Avapritinib; 1703793-34-3; BLU-285; Ayvakit; (1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2, 1-f][1, 2, 4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine; 513P80B4YJ; C-366; 70C366; DTXSID301027935; X720776; X-720776; (1S)-1-(4-fluorophenyl)-1-(2-{4-[6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2, 1-f][1, 2, 4]triazin-4-yl]piperazin-1-yl}pyrimidin-5-yl)ethan-1-amine; (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO(2, 1-F)(1, 2, 4)TRIAZIN-4-YL)PIPERAZIN-YL)PYRIMIDIN-5-YL)ETHAN-1-AMINE; avapritinibum; (1S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO(2, 1-F)(1, 2, 4)TRIAZIN-4-YL)PIPERAZIN-1-YL)PYRIMIDIN-5-YL)ETHAN-1-AMINE; (1S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methylpyrazol-4-yl)pyrrolo(2, 1-f)(1, 2 and 4)triazin-4-yl)piperazin-1-yl)pyrimidin-5-yl)ethanamine; RefChem:56916; DTXCID501513502; CS3007; PDGFR alpha/KIT Mutant-specific Inhibitor BLU-285
(1S)-1-(4-fluorophenyl)-1-[2-[4-[6-(1-methylpyrazol-4-yl)pyrrolo[2, 1-f][1, 2 and 4]triazin-4-yl]piperazin-1-yl]pyrimidin-5-yl]ethanamine
InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1